Keywords: la, jolla/leo, pharmaceutical, ljp, deal, jolla, pharmaceuticals
La Jolla/Leo Pharmaceutical LJP 394 deal
Article | 25 September 1995
- La Jolla Pharmaceuticals has licensed marketing rights in Europe and the Middle East for LJP 394, its candidate drug for lupus ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
